Enjoy complimentary customisation on priority with our Enterprise License!
The global proteinuria therapeutics market has the potential to grow by USD 81.83 million during 2019-2023. The growth momentum will accelerate throughout the forecast period and the market will grow at a CAGR of almost 3%.
The growing geriatric population and the introduction of smartphone-based diagnosis and treatment are some of the major factors driving market growth. The US, the UK, and Canada are currently the major markets for proteinuria therapeutics.
The report provides a detailed analysis of the market by product and geography. Also, the proteinuria therapeutics market forecast report analyzes the market's competitive landscape and offers information on several market vendors.
Browse TOC and LoE with selected illustrations and example pages from proteinuria therapeutics market report
The proteinuria therapeutics market is fragmented, and the degree of fragmentation will increase during the forecast period. With the rising kidney related diseases and other health issues, vendors and governmental bodies are taking efforts to increase awareness about various kidney diseases along with proteinuria. AbbVie Inc., AstraZeneca Plc, and Boehringer Ingelheim International GmbH are some of the major market participants. Though the accelerating growth momentum will offer immense growth opportunities, the lack of curative therapies will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The report provides information on the production, sustainability, and prospects of several companies, including:
The prevalence of proteinuria increases with age and the rapid advances in healthcare and the availability of advanced treatment options have increased the life expectancy of people, leading to a rise in the geriatric population. This will result in an increase in number of proteinuria cases, driving the need for effective therapeutics. Considering the potential usage of proteinuria, vendors are focusing on developing novel therapies to reduce proteinuria.
Moreover, proteinuria is also common among people with a history of renal diseases. Proteinuria can also be caused by diseases such as multiple myeloma, AIDS, lupus, and rheumatoid arthritis. The prevalence of these risk factors will also drive the need for proteinuria therapeutics over the forecast period.
For more insights on the proteinuria therapeutics market share of various regions Request for a FREE sample now!
North America is a major market for proteinuria therapeutics. The growing sales of off-label drugs and the increasing prevalence of various associated risk factors for proteinuria are driving market growth in the region. The high prevalence of the risk factors for proteinuria is also increasing the adoption of therapeutics for its treatment.
During the forecast period, over 51% of the overall market growth will originate from North America. However, market growth in this region will be slower than the growth of the market in Asia.
Request for a FREE sample and Get more information on the market contribution of various product segments
ACE inhibitors help to relax the veins and arteries to lower the blood pressure and prevent an enzyme in the body from producing angiotensin II which narrows the blood vessels. They are highly preferred by medicine manufacturers and clinicians. As a result, the proteinuria therapeutics market size will increase in this segment during the forecast period.
This proteinuria therapeutics market analysis report provides an accurate prediction of the contribution of various segments to the growth of the market.
We can help! Our analysts can customize this report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
PART 15: EXPLORE TECHNAVIO
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.